The neoepitope landscape of breast cancer: implications for immunotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The neoepitope landscape of breast cancer: implications for immunotherapy

Published:2019-03-04 Issue:1 Volume:19 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Narang Pooja,Chen Meixuan,Sharma Amit A.,Anderson Karen S.,Wilson Melissa A.^ORCID

Funder

Breast Cancer Research Foundation

School of Life Sciences and The Biodesign Institute at Arizona State University

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-019-5402-1.pdf

Reference64 articles.

1. Menon S, Shin S, Dy G. Advances in Cancer immunotherapy in solid tumors. Cancers (Basel). 2016;8:106.

2. Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390:1853–62.

3. Vansteenkiste J, et al. Prospects and progress of atezolizumab in non-small cell lung cancer. Expert Opin Biol Ther. 2017;17:781–9.

4. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.

5. Hassel JC. Ipilimumab plus nivolumab for advanced melanoma. Lancet Oncol. 2016;17:1471–2.

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advanced Insights into Competitive Endogenous RNAs (ceRNAs) Regulated Pathogenic Mechanisms in Metastatic Triple-Negative Breast Cancer (mTNBC);Cancers;2024-09-01

2. Whole exome-seq and RNA-seq data reveal unique neoantigen profiles in Kenyan breast cancer patients;2024-06-20

3. Public neoantigens in breast cancer immunotherapy (Review);International Journal of Molecular Medicine;2024-06-17

4. Converging and evolving immuno-genomic routes toward immune escape in breast cancer;Nature Communications;2024-02-21

5. Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies;Cancer Cell;2024-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3